+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Insulin Glargine Market 2021-2025

  • PDF Icon

    Report

  • June 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5345901
Insulin Glargine is a long-acting human insulin analog that can control the patient's blood sugar more effectively and steadily. It is often used to treat type 1 and type 2 diabetes. Its original research manufacturer is Sanofi, and its trade name is Lantus, which came to the Chinese market in 2004. In 2020, in addition to the original research company, other manufacturers in the Chinese Insulin Glargine market are Gan&Lee Pharmaceuticals Co., Ltd. and Zhuhai United Laboratories Co., Ltd.

According to the market research, the sales value of Insulin Glargine has shown an upward trend from 2016 to 2020 in China, reaching CNY960.49 million in 2020. Sales growth in 2020 has slowed down compared to previous years. The main reason is that the COVID-19 epidemic has impacted the hospital's overall diagnosis and treatment business. The CAGR of the sales value of Insulin Glargine in the Chinese market is 5.45% from 2016 to 2020.

The analyst predicts that from 2021 to 2025, the sales of Insulin Glargine in China will have a recovery growth with the improvement of the epidemic and the normal operation of the hospital's overall diagnosis and treatment business. In addition, its sales will also increase due to market expansion. The number of diabetic patients in China has ranked the first in the world, and there is a great demand for diabetes treatment drugs. Insulin Glargine belongs to the third generation of insulin. Compared with other types of insulin, third-generation insulin has greater advantages in terms of onset time, peak performance, and duration of action, indicating that the Insulin Glargine market has room for growth in China. In addition, the key patent of Insulin Glargine expired in 2015, and more generic drugs will appear in the Insulin Glargine market in the future. Therefore, the price of Insulin Glargine is expected to continue to fall, driving sales volume to increase sales.

Topics Covered:

  • The impact of COVID-19 on China's Insulin Glargine market
  • Sales value of China's Insulin Glargine 2016-2020
  • Competitive landscape of China's Insulin Glargine market
  • Prices of Insulin Glargine in China
  • Prices of Insulin Glargine in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Insulin Glargine market
  • Prospect of China's Insulin Glargine market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Insulin Glargine
1.1 Indications for Insulin Glargine
1.2 Development of Insulin Glargine in China
1.3 Governmental Approval of Insulin Glargine in China
1.4 The Impact of COVID-19 on Insulin Glargine Sales in China
2 Sales of Insulin Glargine in China, 2016-2020
2.1 Sales Value of Insulin Glargine
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Insulin Glargine
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Insulin Glargine by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Insulin Glargine Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Insulin Glargine Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales Volume
3.2 Sanofi-Aventis Deutschland GmbH Germany
3.2.1 Enterprise Profile
3.2.2 Sales of LANTUS &TOUJEO (Sanofi-Aventis Deutschland GmbH Germany’s Insulin Glargine) in China
3.3 Gan&Lee Pharmaceuticals Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of BASALIN (Gan&Lee Pharmaceuticals Co., Ltd.’s Insulin Glargine) in China
3.4 Zhuhai United Laboratories Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of USLEN (Zhuhai United Laboratories Co., Ltd.’s Insulin Glargine) in China
4 Prices of Insulin Glargine for Different Manufacturers in China, 2020-2021
4.1 Sanofi-Aventis Deutschland GmbH Germany (LANTUS &TOUJEO)
4.2 Gan&Lee Pharmaceuticals Co., Ltd. (BASALIN)
4.3 Zhuhai United Laboratories Co., Ltd. (USLEN)
5 Prospect of Chinese Insulin Glargine Market, 2021-2025
5.1 Influential Factors of Chinese Insulin Glargine Market Development
5.1.1 The Impact of COVID-19 on Chinese Insulin Glargine Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Insulin Glargine Injection Registration in China
Chart Sales Value of Insulin Glargine Injection over the World
Chart Sales Value of Insulin Glargine Injection in China, 2016-2020
Chart Sales Value of Insulin Glargine Injection in China by Region, 2016-2020
Chart Sales Volume of Insulin Glargine Injection in China, 2016-2020
Chart Sales Volume of Insulin Glargine Injection in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Insulin Glargine Manufacturers in China, 2016-2020
Chart Sales Value and Volume of LANTUS &TOUJEO in China, 2016-2020
Chart Sales Value and Volume of BASALIN in China, 2016-2020
Chart Sales Value and Volume of USLEN in China, 2016-2020
Chart Referential Prices of LANTUS &TOUJEO in China by Region, 2020-2021
Chart Referential Prices of BASALIN in China by Region, 2020-2021
Chart Referential Prices of USLEN in China by Region, 2020-2021
Chart Forecast on Sales Value of Insulin Glargine in China, 2021-2025
Chart Forecast on Sales Volume of Insulin Glargine in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  • Sanofi-Aventis Deutschland GmbH Germany
  • Gan&Lee Pharmaceuticals Co., Ltd.
  • Zhuhai United Laboratories Co., Ltd

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Table Information